Hemastatx GmbH develops targeted therapies for severe bleeding disorders and is advancing HMX-001, a monoclonal antibody program for von Willebrand factor (VWF)–related bleeding disorders. HMX-001 is designed to inhibit ADAMTS13 activity to preserve functional high‑molecular‑weight VWF multimers and help control bleeding episodes.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
✓ Offered
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
First-in-class monoclonal antibody therapy to prevent bleeding in VWF-related bleeding disorders; targets ADAMTS13, preserves HMW-VWF multimers, and addresses acquired as well as congenital forms.
Knowledge
No knowledge articles yet
Once Hemastatx GmbH has claimed this profile, we'll publish editorial articles and case studies here together.